Trial Profile
Assessment of 18F-Florbetaben Whole-body PET Imaging for the Comprehensive Detection of Cardiac and Extracardiac Sites of Amyloid Deposits
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 17 Jan 2024
Price :
$35
*
At a glance
- Drugs Florbetaben F18 (Primary)
- Indications Amyloid light-chain amyloidosis; Amyloidosis
- Focus Diagnostic use
- Acronyms CAPRI
- 10 Jan 2024 Planned End Date changed from 10 May 2024 to 10 May 2025.
- 10 Jan 2024 Planned primary completion date changed from 30 Dec 2023 to 30 Jan 2025.
- 28 Nov 2023 Planned End Date changed from 1 Dec 2022 to 10 May 2024.